Rapport Therapeutics, Inc.
RAPP
$27.62
-$0.22-0.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.76M | -26.93M | -26.73M | -24.06M | -19.98M |
| Total Depreciation and Amortization | 265.00K | 256.00K | 252.00K | 244.00K | 260.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.19M | 5.51M | 4.78M | 4.02M | 3.93M |
| Change in Net Operating Assets | 3.61M | 3.70M | -3.37M | -433.00K | 1.34M |
| Cash from Operations | -24.70M | -17.47M | -25.07M | -20.24M | -14.45M |
| Capital Expenditure | -169.00K | -134.00K | -22.00K | -291.00K | -226.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -174.16M | -56.64M | 22.62M | 21.32M | 32.16M |
| Cash from Investing | -174.32M | -56.78M | 22.60M | 21.03M | 31.93M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 311.00K | 270.47M | 0.00 | 6.00K | 7.00K |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -1.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 63.00K | -63.00K | -- | -- |
| Cash from Financing | 311.00K | 270.53M | -63.00K | 5.00K | 7.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -198.71M | 196.29M | -2.54M | 799.00K | 17.49M |